Tenax Therapeutics, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Chapel Hill, NC
TENX chart
What traders are saying about $TENX
Latest postsTenax Therapeutics, Inc. news
- What's Next for Tenax Therapeutics, Inc. Shareholders After 89.77% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline
PR Newswire ·
- Tenax Therapeutics, Inc. (TENX) Stock Price, News, Quote & History
Yahoo! Finance Canada ·
- Tenax Therapeutics (TENX) Upgraded to Buy: Here's Why
Yahoo Finance ·
- TENX DEADLINE: Levi & Korsinsky Reminds Tenax Therapeutics,
GlobeNewswire ·
- INVESTOR DEADLINE: Tenax Therapeutics, Inc. (TENX) Investors with Substantial Losses May Seek to Lead Class Action Lawsuit Before December 28, 2026 Deadline
PR Newswire ·
- SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against Tenax Therapeutics, Inc. (NASDAQ: TENX) — Investors Who Suffered Losses Are Encouraged to Contact the Firm
mykxlg.com ·
- ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Tenax Therapeutics, Inc. Investors to Secure ...
Black Hills Pioneer ·
- TENX Investors Have Opportunity to Lead Tenax Therapeutics, Inc. Securities Fraud Lawsuit
The Journal Gazette ·
- TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law
Eastern Progress ·
- Tenax Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - TENX
Eastern Progress ·
- TENX Investor Alert: Johnson Fistel Encourages Tenax Therapeutics, Inc. Investors to Contact the Firm Ahead of December 28, 2026 Lead Plaintiff Deadline
GlobeNewswire ·
- What Should Tenax Therapeutics, Inc. Investors Know After 89.77% Stock Drop? The Law Offices of Frank R. Cruz Outlines Securities Fraud Class Action Lead Plaintiff Deadline
Morningstar ·
Tenax Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0 | – | – |
| Net income | -$52.6M | -$17.6M | -$7.7M | $11.0M |
| Diluted EPS | $-1.34 | $-1.15 | $-31.04 | – |
| Total assets (year end) | $104.2M | $96.7M | $11.7M | $3.4M |
| Cash and equivalents (year end) | $97.6M | $94.9M | $9.8M | $2.1M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Tenax Therapeutics, Inc.
- Ticker
- TENX (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Chapel Hill, NC
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 34956
- Former names
- OXYGEN BIOTHERAPEUTICS, INC., SYNTHETIC BLOOD INTERNATIONAL INC
Frequently asked questions
What exchange is Tenax Therapeutics, Inc. listed on?
Tenax Therapeutics, Inc. trades on the Nasdaq under the ticker symbol TENX.
What industry is Tenax Therapeutics, Inc. in?
Tenax Therapeutics, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Tenax Therapeutics, Inc. headquartered?
Tenax Therapeutics, Inc.'s business address on file with the SEC is in Chapel Hill, NC.
When does Tenax Therapeutics, Inc.'s fiscal year end?
Tenax Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Tenax Therapeutics, Inc. report?
Tenax Therapeutics, Inc. reported $0 in revenue for calendar year 2025, according to its SEC filings.